SecBot SecBot
PRESS-RELEASE ·Filed Jul 1, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

FDA green light for US Part 2 enrollment is a positive catalyst that reduces trial risk; monitor for IND amendment submission and initiation of US sites. TLX591-Tx's differentiated safety profile could support a competitive advantage in the prostate cancer therapy landscape.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

TLX drug pipeline →

TLX591-Tx

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
Next catalyst
None dated

What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.87
T+0 close · Jul 1, 2026 · via day close
Latest settled
−4.72%
T+60 · $11.31
Vs SPY
−7.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $11.87entry
  2. T+1 · 4mo ago +2.36%α +1.49% · $12.15
  3. T+5 · 4mo ago −0.76%α −1.69% · $11.78
  4. T+20 · 4mo ago −15.25%α −14.83% · $10.06
  5. T+60 · 7w ago −4.72%α −7.73% · $11.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix announced FDA alignment to proceed to Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, following successful review of safety data from Part 1. The FDA agreed on the clinical protocol and statistical plan, allowing US enrollment to begin upon IND amendment submission. This regulatory milestone de-risks the pivotal trial and supports TLX591-Tx's differentiated profile with no observed kidney toxicity.

Key Facts

  • FDA confirmed Part 1 safety data sufficient to start Part 2 of ProstACT Global trial in the US.
  • TLX591-Tx (177Lu rosopatamab tetraxetan) targets PSMA in metastatic castration-resistant prostate cancer.
  • Two-dose regimen administered 14 days apart, combined with abiraterone, enzalutamide, or docetaxel.
  • TLX591-Tx shows no significant kidney toxicity and minimal salivary/lacrimal uptake vs. other PSMA-targeted radioligand therapies.
  • Part 2 enrollment already underway in multiple countries (Australia, NZ, Canada, Turkey, UK, China, Singapore, South Korea).

Financial Impact

FDA alignment on Phase 3 protocol reduces regulatory risk and supports pipeline value; TLX market cap ~$3.9B

pipeline valueregulatory probability of success

Risk Factors

  • IND amendment still pending FDA review before US enrollment can begin.
  • Competition from existing PSMA-targeted radioligand therapies (e.g., Pluvicto).
  • Enrollment delays or unexpected safety signals in Part 2 could impact timeline.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3321065

Track record

27 reports on TLX

Performance horizon

9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026